Study of ABO2102 in KRAS-Mutated Solid Tumors

Inclusion criteria

• ≥18 years of age at time of informed consent.
• Have a genetically tested report confirmed by the investigator or complete genetic testing during the screening period, with evidence of harboring any of required KRAS mutations
• Histopathologically and/or cytologically confirmed locally advanced or metastatic solid tumors.
• According to RECIST v1.1, at least one measurable lesion is required.
• No severe hematological, hepatic, renal or coagulation dysfunction; laboratory test results during the screening period must meet the respective criteria specified in the study protocol.
• Females of childbearing potential and males who are involved in heterosexual activity must agree to practice highly effective contraception.

Exclusion criteria

• Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix.
• Has known symptomatic central nervous system (CNS) metastases, or CNS metastases requiring local CNS-directed therapy .
• Received KRAS cancer vaccine before.
• History of severe (≥ Grade 3) hypersensitivity reactions to immunotherapy.
• History of allogeneic organ transplantation or graft-versus-host disease (GVHD).
• Any active infection (except for hepatitis virus infection) requires systemic treatment.
• Absence of spleen
• Known psychiatric disorder or drug abuse that may interfere with the trial requirements
• Participant is pregnant or breastfeeding or expecting to conceive within the projected duration of the study.
• Other conditions that Investigators consider inappropriate for enrollment.